trending Market Intelligence /marketintelligence/en/news-insights/trending/nAdXt6HbtgI2am7h0v1gHQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Report: Super-Pharm in talks for Teva plant

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Report: Super-Pharm in talks for Teva plant

Super-Pharm is in discussion to acquire Teva Pharmaceutical Industries Ltd.'s manufacturing plant in Ashdod, Israel, Reuters reported, citing a source familiar with the matter.

The pharmacy chain is expected to pay 60 million shekels to 80 million shekels for the plant and retain its 70 workers, the source added.

Teva's Ashdod plant mostly involves the preparation of liquid medications such as antibiotics and chemotherapy as well as food for premature babies.

Teva recently announced a $3 billion restructuring plan which would see the company let go of some 14,000 employees worldwide and the potential sale of a number of its assets.

As of Dec. 25, US$1 was equivalent to 3.48 New Israeli shekels.